Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Weijiexin Biological Technology

Request full access

Recombinant protein and antibody drugs for veterinary use

Haidian, ChinaFounded 2016Biotech & Life Sciences

About Weijiexin Biological Technology

Beijing Weijiexin Biological Technology Co., Ltd. (VJTbio) is a biopharmaceutical company established in 2016, specializing in the research, development, production, and sale of innovative drugs for the animal health sector. The company was founded by Dr. Luo Haoshu, a reproductive endocrinology expert and researcher at the State Key Laboratory of Agrobiotechnology at China Agricultural University. Dr. Luo's academic background in reproductive diseases and gene-engineered drugs, combined with a desire to translate research into practical applications, led to the creation of VJTbio.

VJTbio focuses on developing advanced animal drugs, particularly recombinant protein and antibody therapeutics, often considered Class 1 new veterinary drugs in China. The company's product pipeline targets three main areas: animal reproduction, disease prevention and control, and pet diseases. Key products include a long-acting recombinant porcine follicle-stimulating hormone for synchronized breeding in livestock, cytokine products to prevent and treat diseases like porcine epidemic diarrhea virus (PEDV), and antibody drugs for conditions in cats and dogs such as tumors, autoimmune diseases, and pain. Many of its products are first-in-class globally and are protected by international PCT patents.

The company operates a comprehensive industrial chain, from initial R&D and clinical trials to large-scale production and sales. Its R&D headquarters are in Beijing, and it runs a GMP-certified production facility in Taizhou, Zhejiang, which is one of the largest and most advanced domestic plants for producing animal protein drugs via mammalian cell culture. VJTbio has received significant financial backing, completing a Series B funding round of over 100 million RMB in 2020 and a Series C round for several hundred million RMB in 2023, with investors including SDIC Capital and China Life Equity Investment.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
2
Dealroom signal
23.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC May 2023 $28M $220M Capital Development Investment Fund · Xinshang Capital · FC Capital · Beijing Zhongguancun Science City Innovation Development ↗
SPINOUT✓Other financing Jan 2016 $0 — China Agricultural University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Weijiexin Biological Technology website traffic

Latest recorded traffic for Weijiexin Biological Technology is 660 monthly website visits, down 25% over the last three months.

Latest monthly visits660 3-month web change-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Weijiexin Biological Technology in the Haidian ecosystem

Live from Dealroom

The Weijiexin Biological Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later8 investors entered at this stage

  • Capital Development Investment Fund
  • Xinshang Capital
  • FC Capital
  • Beijing Zhongguancun Science City Innovation Development
  • China Life Private Equity Investment
  • SDIC Venture Capital
  • Shunde Science and Technology Group(Kecan Group)
  • Shanghai STVC Group

Other known investors1 additional known investor

  • China Agricultural University
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Haidian HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Weijiexin Biological Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Weijiexin Biological Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.